**HBV-HCC: basic and clinical 1**

June 24, 2022（Friday）08:00-09:40 (GMT+8)

* Moderator：Jia-Horng Kao (Taiwan)
* Moderator：Young-Suk Lim (South Korea)
* Conference Room：301

| Time | Topic | Speaker |
| --- | --- | --- |
| 08:00-08:25 | Natural history and carcinogenesis of HBV infection | Rong-Nan Chien (Taiwan) |
| 08:25-08:50 | Biomarkers predictive of HBV-HCC | Tai-Chung Tseng (Taiwan) |
| 08:50-09:15 | Risk prediction models of HBV-HCC | Hwai-I Yang(Taiwan) |
| 09:15-09:40 | Prevention of HBV-HCC (primary, secondary and tertiary prevention) | Young-Suk Lim (South Korea) |

**HCV-HCC: basic and clinical 2**

June 24, 2022（Friday）08:00-09:40 (GMT+8)

* Moderator：Ming-Lung Yu (Taiwan)
* Moderator：Yasuhito Tanaka (Japan)
* Conference Room：401

| Time | Topic | Speaker |
| --- | --- | --- |
| 08:00-08:25 | Risk stratification of HCV-HCC before and after HCV cure | Chen-Hua Liu (Taiwan) |
| 08:25-08:50 | Genetic factors associated with HCC development after HCV eradication | Yasuhito Tanaka (Japan) |
| 08:50-09:15 | Molecular Mechanisms Driving HCC of HCV-HCC after HCV cure | Thomas F. Baumert (Germany) |
| 09:15-09:40 | Prognosis of HCV-HCC: Does HCV-HCC have better responses to target/immunotherapy? | Ming-Lung Yu (Taiwan) |

**MAFLD/NASH-HCC: basic and clinical 3-1**

June 24, 2022（Friday）10:00-11:40 (GMT+8)

* Moderator：Han-Chieh Lin (Taiwan)
* Moderator：Bin Gao (USA)
* Conference Room：301

| Time | Topic | Speaker |
| --- | --- | --- |
| 10:00-10:25 | Pathogenesis of NASH and Liver Fibrosis | Kuei-Chuan Lee (Taiwan) |
| 10:25-10:50 | Inflammation in fatty liver disease progression and liver cancer | Bin Gao (USA) |
| 10:50-11:15 | MAFLD and NAFLD diagnostic criteria and prevalence of fibrosis in Asia and Western patients  | Jacob George (Australia) |
| 11:15-11:40 | Biomarkers for NAFLD/NASH and its treatment response | Vincent Wong (Hong Kong) |

**MAFLD/NASH-HCC: basic and clinical 3-2**

June 24, 2022（Friday）13:00-14:40 (GMT+8)

* Moderator：Chia-Yen Dai (Taiwan)
* Moderator：Daniel Q. Huang (Singapore) -已邀請，尚未回覆
* Conference Room：301

| Time | Topic | Speaker |
| --- | --- | --- |
| 13:00-13:30 | Global Epidemiology of NAFLD-related HCC: trends, risk factors, and surveillance | Daniel Q. Huang (Singapore) |
| 13:30-14:00 | Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts | William Alazawi (UK) |
| 14:00-14:30 | Diabetes and the risk of hepatocellular carcinoma in cirrhosis patients with NAFLD | Ju Dong Yang (South Korea) |
| 14:30-14:40 | Session Closing |  |

**HCC basic science, genomic and molecular pathogenesis 4-1**

June 24, 2022（Friday）10:00-11:40 (GMT+8)

* Moderator：Shiou Hwei Yeh (Taiwan)
* Moderator：Hidewaki Nakagawa (Japan)
* Conference Room：401

| Time | Topic | Speaker |
| --- | --- | --- |
| 10:00-10:25 | Cell-matrix interaction in the invasion and metastasis of liver cancer | Sen-Yung Hsieh (Taiwan) |
| 10:25-10:50 | Proteo-genomic Characterization of Virus-associated Liver Cancers Identifies Novel Subtypes and Therapeutic Strategies | Hidewaki Nakagawa (Japan) |
| 10:50-11:15 | Tumor-intrinsic mechanisms regulate immune exclusion in liver cancers | Amaia Lujambio (Spain) |
| 11:15-11:40 | (TBD) | Daniela Sia (USA) |

備註：11:15-11:40 Lars Zender替換為Daniela Sia，已確認邀約。

**HCC basic science, immunopathogenesis and microenvironment 4-2**

June 24, 2022（Friday）13:00-14:40 (GMT+8)

* Moderator：Chun-Yen Lin (Taiwan)
* Moderator：JunHao Hu (China)
* Conference Room：401

| Time | Topic | Speaker |
| --- | --- | --- |
| 13:00-13:25 | Immune regulation in tumor immunotherapy | Chun-Yen Lin (Taiwan) |
| 13:25-13:50 | Hepatic stellate cell activation roadmap in liver fibrosis and its application | JunHao Hu (China) |
| 13:50-14:15 | The role of CD4+ T cell in the HCC treatment | Tim F. Greten (Germany) |
| 14:15-14:40 | The role of innate/adaptive immune cells in NASH - consequences for liver cancer therapy | Mathias Heikenwalder (Germany) |

State-of-Art Lecture

June 24, 2022（Friday）15:20-15:50 (GMT+8)

* Moderator：Han-Chieh Lin (Taiwan)
* Conference Room：201
* Speaker：Chien-Jen Chen (Taiwan)
* Topic：National policy and achievement of HCC control in Taiwan

Chairman Lecture

June 24, 2022（Friday）15:50-16:20 (GMT+8)

* Moderator：Pei-Jer Chen (Taiwan)
* Conference Room：201
* Speaker：Chun-Jen Liu (Taiwan)
* Topic：Towards elimination of HBV-related HCC: What we learn from Prof. DS Chen.

Keynote Lecture (1)

June 24, 2022（Friday）16:20-16:50 (GMT+8)

* Moderator：Chien-Jen Chen (Taiwan)
* Conference Room：201
* Speaker：Pei-Jer Chen (Taiwan)
* Topic：Recent Progress and Future Directions of HCC Systemic Therapies: The need for HCC-specific targets and regimens